Jim Simons Achilles Therapeutics PLC Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,005,759 shares of ACHL stock, worth $955,471. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,005,759

Previous 498,995 101.56%

Holding current value

$955,471

Previous $444,000 183.11%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.82 - $1.57 $415,546 - $795,619	506,764 Added 101.56%	1,005,759 $1.26 Million
Q4 2023 Feb 13, 2024	BUY	$0.78 - $0.96 $47,944 - $59,008	61,467 Added 14.05%	498,995 $444,000
Q3 2023 Nov 14, 2023	SELL	$0.84 - $1.11 $10,252 - $13,547	-12,205 Reduced 2.71%	437,528 $398,000
Q2 2023 Aug 11, 2023	BUY	$0.82 - $1.09 $56,990 - $75,755	69,500 Added 18.28%	449,733 $425,000
Q1 2023 May 12, 2023	SELL	$0.84 - $1.26 $87,780 - $131,670	-104,500 Reduced 21.56%	380,233 $364,000

Q4 2022 Feb 13, 2023	BUY	$0.79 - $2.02 $318,923 - $815,474	403,700 Added 498.19%	484,733 $436,000
Q3 2022 Nov 14, 2022	SELL	$2.34 - $3.38 $14,508 - $20,956	-6,200 Reduced 7.11%	81,033 $183,000
Q2 2022 Aug 12, 2022	BUY	$1.96 - $3.04 $111,132 - $172,368	56,700 Added 185.7%	87,233 $220,000
Q1 2022 May 13, 2022	BUY	$2.8 - $5.23 $14,000 - $26,150	5,000 Added 19.58%	30,533 $90,000
Q4 2021 Feb 11, 2022	BUY	$4.22 - $8.86 $107,749 - $226,222	25,533 New	25,533 $128,000

Others Institutions Holding ACHL

# of Institutions

Shares Held

23.5M

Call Options Held

Put Options Held

View Full List

About Achilles Therapeutics plc

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $38.7M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

More about ACHL

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account